CA-ANOMALI
16.12.2021 11:02:04 CET | Business Wire | Press release
Anomali , the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions, today announced that multi-decade industry veteran Justin Coker has been named Vice President and General Manager of Europe and the Middle East (EMEA). Coker takes the region’s helm during a period of explosive demand for Anomali’s leading cybersecurity solutions, which are delivering unmatched ability in precision threat detection and comprehensive response that stops immediate and future breaches and attacks.
“Anomali is building a world-class leadership team as we continue on our phenomenal growth trajectory around the world. Justin brings a powerful combination of experience and skill to ensure that our public and private sector customers and partners receive the attention needed to build efficient, high-performance security infrastructures that stop advanced breaches and the attackers targeting their enterprises,” said Ahmed Rubaie, CEO, Anomali. “We are excited to welcome Justin to the company; his commitment to the organization and regional expertise makes him the perfect leader for the job.”
Coker has spent more than 20 years in senior sales management roles at leading enterprise cybersecurity companies. He joins Anomali from IronNet Cybersecurity, where, as VP of EMEA, he built out a sales team from the ground up on its journey to its recent IPO. Prior to then, he was VP of EMEA at Skybox Security, where he grew the business from a start-up to a team of 50, along the way winning a comprehensive list of EMEA's largest organizations as customers and creating strong alliances with many of the premier partner organizations across the region. Before that, while at Symantec, he led the United Kingdom’s and Ireland's retail banking and finance enterprise sales team for five years. He has held other successful IT sales positions at AXENT Technologies, Parametric Technology, and Fujitsu. Throughout his professional career, Coker has exceeded expectations at building and scaling successful sales teams and has remained enthusiastic about delivering business value to his clients and partners.
“I am excited to be joining Anomali at such a pivotal phase of growth and innovation. I look forward to driving our deeper portfolio adoption across EMEA through the development of existing and new markets, coupled with the continued expansion of our global channel and technology partner ecosystem,” said Coker. “Anomali’s go-to-market approach in EMEA is centered around our continued passion for creating strong partnerships with our global enterprise clients and helping them capitalize upon significant business value. I look forward to fulfilling our mission to strengthen customers’ security efficacy and efficiency, fueled by our intelligence-driven detection and response solutions and world-class customer-focused team.”
Coker and his team will be furthering access to the award-winning Anomali portfolio, which includes ThreatStream, our leading threat management platform, Lens, the industry’s only Natural Language Processing (NLP) product that identifies all threats and IOCs in any web content to operationalize them across security infrastructures, and Match, our advanced global attacker detection and response solution that quickly identifies and responds to threats in real-time by automatically correlating all security telemetry data against active threat intelligence.
Twitter:
https://twitter.com/Anomali
LinkedIn:
https://www.linkedin.com/company/anomali/
Blog:
https://www.anomali.com/blog
Detect LIVE Conference:
https://www.anomali.com/detect-live
About Anomali
Anomali is the leader in intelligence-driven extended detection and response (XDR) cybersecurity solutions. Anchored by big data management and refined by artificial intelligence and machine learning, the Anomali platform delivers proprietary capabilities that correlate an extraordinary volume of telemetry from customer-deployed security solutions with the largest repository of global intelligence, empowering security operations teams to detect threats with precision, optimize response, achieve resiliency, and stop attackers and breaches. Our Cloud-first SaaS-based solutions easily integrate into existing security tech stacks and accommodate hybrid deployments. Founded in 2013, Anomali serves public and private sector organizations, ISACs, MSSPs, and Global 1000 customers worldwide in every major industry. Leading venture firms including Google Ventures, General Catalyst, and IVP back Anomali. Learn more at www.anomali.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215006153/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
